Below are articles from various sources about members of MCB and their research.
What's so great about choanoflagellates? MCB Professor Nicole King explains and reveals why she has dedicated her research career to figuring out how the first multicellular animal life came to be.
Listen to a podcast, hosted by the Journal of Immunology, where Professor David H. Raulet discusses the importance of fundamental research. It highlights how some clinical therapies for cancer have emerged from basic science, performed decades previously, that had no obvious connection to cancer at the time it was published.
Listen to the podcast here.
G. Steven Martin has retired and now Michael Botchan is serving as Interim Dean of Biological Sciences. Our MCB Co-Chairs have had a "changing of the guard" as well -- David Raulet and Richard Harland have handed the reigns over to David Drubin and Nipam Patel. Richard Harland will now serve as Senior Associate Dean of Biological Sciences.
Watch the shared ceremony with the Helen Wills Neuroscience Institute, the Biophysics Graduate Group, the Endocrinology Graduate Group and the Computational Biology Graduate Group. Congratulations to all the graduates!
Congratulations to all the graduates!
Berkeley's Cancer Research Lab, in close collaboration with the Cancer Research Institute, highlights June as Cancer Immunotherapy Month. "As we appreciate these events during this month, it is remarkable to reflect on how the cancer immunotherapy revolution had its roots in basic science done here in the CRL at Berkeley."
MCB Professor Michael Rape has received a 2016 Blavatnik National Awards for Young Scientists. He is recognized for his "for his fundamental discoveries related to ubiquitylation." The award comes with $250,000 in unrestricted funds, the largest award for early-career scientists in the U.S.
This $1.24 million award will be split among MCB Professor Jennifer Doudna, and her collaborator, Emmanuelle Charpentier of the Max Planck Institute of Infection Biology in Germany and Umeå University in Sweden, as well as Feng Zhang of MIT. They were awarded “for the development of CRISPR/Cas9 as a breakthrough genome editing platform that promises to revolutionize biomedical research and disease treatment.”